NEW YORK (GenomeWeb News) – Quest Diagnostics today reported a 3 percent drop in third-quarter revenues, missing consensus Wall Street estimates.

For the quarter ended Sept. 30, the company posted $1.85 billion in revenues, down from $1.91 billion a year ago, and short of the average Wall Street estimate of $1.91 billion.

Clinical testing revenues dropped by 2 percent year over year, with volume, measured by the number of requisitions, down about 1 percent, and revenue per requisition also down 1 percent, Quest said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.